Evidence map›Paper›PMID 38862441›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer

F Li, J Xiang, J Liu, X Wang, H Jiang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. LncRNA FEZF1-AS1 promotes the tumorigenesis and suppresses ferroptosis in non-small cell lung cancer through the TNF-α/NF-κB pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

F LiDepartment of Tumor Radiotherapy, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
J XiangDepartment of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
J LiuDepartment of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
X WangDepartment of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
H JiangDepartment of Tumor Radiotherapy, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the molecular mechanism by which FEZF1-AS1 overexpression promotes progression of nonsmall cell lung cancer (NSCLC) via the miR-130a-5p/CCND1 axis.

methodsTCGA database was used to analyze FEZF1-AS1 expression levels in NSCLC. FEZF1-AS1 expression was detected by qRT-PCR in clinical specimens of NSCLC tissues and NSCLC cell lines, and its correlation with clinical features of the patients were analyzed. The binding sites of FEZF1-AS1 with hsa-miR-130a-5p and those of hsa-miR-130a-5p with CCND1 were predicted. CCK8 assay, clone formation assay, scratch assay, and Transwell assay were employed to examine the effects of FEZF1-AS1 knockdown and hsa-miR-130a-5p inhibitor on proliferation, invasion, and migration abilities of lung cancer cell lines. Dual luciferase assay was used to verify the binding of FEZF1-AS1 with hsa-miR-130a-5p and the binding of hsa-miR-130a-5p with CCND1. Western blotting was performed to detect the changes in CCND1 protein expression level in H1299 and H358 cells following FEZF1-AS1 knockdown and treatment with hsa-miR-130a-5p inhibitor.

resultsFEZF1-AS1 was highly expressed in NSCLC tissues in close correlation with lymph node metastasis and also in H1299 and H358 cell lines (all

conclusionFEZF1-AS1 is highly expressed in NSCLC tissue in close correlation with lymph node metastasis to promote cancer progression through the miR-130a-5p/CCND1 axis.

Indexed as

Carcinoma, Non-Small-Cell LungCell MovementCell ProliferationCyclin D1Lung NeoplasmsMicroRNAsRNA, Long NoncodingCell Line, TumorDisease ProgressionDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessRepressor ProteinsCCND1 protein, humanCyclin D1DNA-Binding ProteinsFEZF1 protein, humanMicroRNAsMIRN130 microRNA, humanRepressor ProteinsRNA, Long NoncodingCCND1FEZF1-AS1lncRNAmiR-130a-5pnon-small cell lung cancer

Identifiers

PMID38862441
PMCPMC11166728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.